Run Time: 5 minutes
Author: Peter Bakes M.D.
- Xarelto, Eliquis, Pradaxa, Edoxaban, and Coumadin are all used as anticoagulation.
- Xarelto, Eliquis, Pradaxa, and Edoxaban have been shown to have an increased efficacy for patients with non-valvular atrial fibrillation when compared with Coumadin, which was the standard of care.
- Coumadin is shown to have increased efficacy for patients with valvular atrial fibrillation.
- The newer anticoagulants and Coumadin where shown to be equally effective for PE/DVT.
- 12 studies have been done on the safety of new anticoagulants as compared to Coumadin. In patients with major bleeding before reversal agents, the relative risk is 0.7 or 30% less major bleeding events in the new anticoagulants as compared to Coumadin. There is 60% less risk of intracranial hemorrhage and 50% less risk of bleeding complications leading to death.
- Coumadin is $5 per month, newer ones are $250-$300 per month, without lab checks and medication adjustments. Yet, from an insurance perspective the newer medications actually cost less than a patient on Coumadin.
Link to Podcast: http://medicalminute.madewithopinion.com/oral-anticoagulants/